Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synflorix co-administered with Infanrix hexa in preterm infants
2006-002898-47Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2006
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 10-valent pneumococcal conjugate vaccine and pertussis filamentous haemagglutinin in pneumococcal disease, diphtheria, Tetanus and 4 more, sponsored by GSK. Primary endpoint: Occurrence of core fever after vaccination. Started Aug 2006; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccinepertussis filamentous haemagglutinin
03
Conditions
pneumococcal diseasediphtheriaTetanuspertussishepatitis B (HBV)
Beyond the preview
Go deeper on 2006-002898-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002898-47.